660449-17-2

Upstream product

• 394-31-0 2-amino-5-hydroxybenzoic acid 
• 214957-87-6 N-methyl-N-methyloxy-2-benzyloxycarbonylamino-5-hydroxybenzamide 
• 660448-80-6 2-amino-5-{[tert-butyl(dimethyl)silyl]oxy}-N-methoxy-N-methylbenzamide 
• 660448-79-3 benzyl (4-{[tert-butyl(dimethyl)silyl]oxy}-2-{[methoxy(methyl)amino]carbonyl}phenyl)carbamate 
• 214957-88-7 2-{[(benzyloxy)carbonyl]amino}-5-hydroxybenzoic acid 
• 1330529-96-8 (2-amino-5-{[tert-butyl(dimethyl)silyl]oxy}phenyl)(4-methylphenyl)methanone 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 4294-57-9 para-methylphenylmagnesium bromide 
• 5621-60-3 (2-amino-5-bromophenyl)-(4-methylphenyl)methanone 
• 64373-43-9 5-methyl-3-oxo-hexanenitrile 
• 556-24-1 methyl 3-methylbutanoate 
• 4692-98-2 5-bromoisatoic anhydride 
• 660449-04-7 tert-butyl {[6-hydroxy-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-3-yl]methyl}carbamate 
• 660449-03-6 6-hydroxy-4-(4-methylphenyl)-2-(2-methylpropyl)quinoline-3-carbonitrile 

Downstream Products

• 660449-18-3 (2E)-3-[3-{[(tert-butoxycarbonyl)amino]methyl}-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]prop-2-enoic acid 
• 1262394-33-1 ethyl 3-[3-{[(tert-butoxycarbonyl)amino]methyl}-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]propanoate 
• 660451-15-0 3-[3-{[(tert-butoxycarbonyl)amino]methyl}-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl]propanoic acid 
• 660449-19-4 tert-butyl ({6-[(1E)-3-amino-3-oxoprop-1-en-1-yl]-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-3-yl}methyl)carbamate 
• 660450-71-5 tert-butyl {[6-(3-amino-3-oxopropyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-3-yl]methyl}carbamate 

Relevant academic research and scientific papers

Discovery of a 3-pyridylacetic acid derivative (TAK-100as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor

Inhibition of dipeptidyl peptidase IV (DPP-4is an exciting new approach for the treatment of diabetes. To date there has been no DPP-4 chemotype possessing a carboxy group that has progressed into clinical trials. Originating from the discovery of the str

Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554

Dipeptidyl peptidase IV (DPP-4) inhibition is a validated therapeutic option for type 2 diabetes, exhibiting multiple antidiabetic effects with little or no risk of hypoglycemia. In our studies involving non-covalent DPP-4 inhibitors, a novel series of quinoline-based inhibitors were designed based on the co-crystal structure of isoquinolone 2 in complex with DPP-4 to target the side chain of Lys554. Synthesis and evaluation of designed compounds revealed 1-[3-(aminomethyl)-4-(4-methylphenyl)-2-(2-methylpropyl)quinolin-6-yl] piperazine-2,5-dione (1) as a potent, selective, and orally active DPP-4 inhibitor (IC50 = 1.3 nM) with long-lasting ex vivo activity in dogs and excellent antihyperglycemic effects in rats. A docking study of compound 1 revealed a hydrogen-bonding interaction with the side chain of Lys554, suggesting this residue as a potential target site useful for enhancing DPP-4 inhibition.